AssetRoom

Latest Diamond or Dud Sign In

Search by Algolia

↵ to select ↑↓ to navigate esc to close

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies

Get started →

Follow Ocugen, Inc.

Get SEC filing alerts via email and in your feed for Ocugen, Inc.

OCGN

Ocugen, Inc.

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company specializing in gene and cell therapies, biologics, and vaccines for retinal diseases, ocular conditions, and respiratory illnesses. Its core platforms include modifier gene therapy for inherited retinal disorders, regenerative cartilage repair, and inhaled mucosal vaccines. The company develops innovative treatments for blindness, degenerative eye diseases, and respiratory infections, leveraging advanced gene delivery, biologic, and vaccine technologies to address unmet medical needs globally.

This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Ocugen, Inc.

Ocugen, Inc. Ocugen Reports Q1 2026 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | 28 days ago | 0 comments

Ocugen, Inc. Ocugen Reports $4.41 Million Collaborative Revenue and $67.85 Million Net Loss for 2025

Via official filing (AI summary) | 3 months ago | 0 comments

Ocugen, Inc. Ocugen Reports 54.3% Revenue Increase but Wider Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

Ocugen, Inc. Ocugen Reports 20% Revenue Growth to $1.37 Million, Faces $14.74 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

Ocugen, Inc. Ocugen Reports 46% Revenue Increase but Faces $15.35 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

Ocugen, Inc. Ocugen Reports $54.05 Million Net Loss for 2024, Revenue Declines to $4.06 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

Ocugen, Inc. Ocugen Reports Mixed Q3 Results, Net Loss Improves but Revenue Declines

Via official filing (AI summary) | over 1 year ago | 0 comments